Overview

Location [1]
3q22.3
Protein [2]
Claudin-18
Synonyms [1]
SFTA5, SFTPJ

CLDN18 is altered in 1.07% of all cancers with conventional glioblastoma multiforme, anaplastic astrocytoma, cutaneous melanoma, B-cell lymphoblastic leukemia/lymphoma, not otherwise specified, and adrenal gland pheochromocytoma having the greatest prevalence of alterations [3].

CLDN18 GENIE Cases - Top Diseases

The most common alterations in CLDN18 are CLDN18 A19V (0.08%), CLDN18 I84T (0.08%), CLDN18 M149V (0.13%), CLDN18 R105H (0.18%), and CLDN18 A19T (0.09%) [3].

CLDN18 GENIE Cases - Top Alterations

Significance of CLDN18 in Diseases

Adenocarcinoma Of The Gastroesophageal Junction +

Gastric Adenocarcinoma +

Malignant Solid Tumor +

Gastric Carcinoma +

Pancreatic Adenocarcinoma +

Pancreatic Carcinoma +

Ovarian Carcinoma +

Cholangiocarcinoma +

Esophageal Adenocarcinoma +

Lung Carcinoma +

Pancreatic Ductal Adenocarcinoma +

References

1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta

2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.

3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.

4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.